Metabolic & Weight Management Clinic Kit

Semaglutide is a GLP-1 receptor agonist that mimics native GLP-1 to stimulate insulin secretion in a glucose-dependent manner while suppressing glucagon release. The Aib substitution at position 2 confers resistance to DPP-IV enzymatic degradation, and the C18 fatty diacid chain enables high-affinity albumin binding, extending its half-life substantially. It also acts on hypothalamic appetite centers to reduce food intake and delay gastric emptying.

Tirzepatide is a dual GIP and GLP-1 receptor agonist that activates both incretin pathways simultaneously. It stimulates insulin secretion, suppresses glucagon in a glucose-dependent manner, and reduces appetite via central and peripheral signaling. The dual receptor engagement provides synergistic metabolic effects beyond GLP-1 agonism alone, including enhanced lipid metabolism and improved insulin sensitivity.

Retatrutide is a triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon (GCGR) receptors. GLP-1 and GIP agonism drive insulin secretion and appetite suppression, while glucagon receptor activation increases energy expenditure and hepatic lipid oxidation. This triple mechanism addresses multiple metabolic pathways for potentially superior metabolic research and metabolic improvement over dual agonists.

AOD9604 is a modified 16-amino acid fragment of human growth hormone spanning residues 176-191 with a tyrosine substitution. It stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) without affecting blood glucose levels or growth parameters. Unlike full HGH, it does not compete for the GH receptor and does not induce IGF-1 elevation or insulin resistance, specifically targeting fat metabolism pathways.

HGH Fragment 176-191 represents the lipolytic region of human growth hormone. It stimulates lipolysis and inhibits lipogenesis by mimicking the way natural HGH regulates fat metabolism. Unlike full-length HGH, this fragment does not compete for the GH receptor, does not stimulate IGF-1 production, and does not affect glucose metabolism or insulin sensitivity. Its mechanism of fat mobilization is thought to involve activation of beta-3 adrenergic receptors in adipose tissue.

L-Carnitine is an amino acid derivative essential for the transport of long-chain fatty acids from the cytoplasm into the mitochondrial matrix via the carnitine shuttle system (CPT-I and CPT-II). Inside mitochondria, fatty acids undergo beta-oxidation for energy production. L-Carnitine also modulates the acyl-CoA/CoA ratio, buffers excess acyl groups, and has antioxidant properties protecting mitochondrial membranes from lipid peroxidation. It enhances fatty acid utilization as an energy substrate, particularly during exercise and caloric restriction.